

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex, Bandra (E)
Mumbai-400051

Date: May 20, 2026

Dear Sir,

Sub.: Issue details for Anchor allocations of IPO of Q-Line Biotech Limited

The Board of director of the company at its meeting held on 20-05-2026, in consultation with the Book Running Lead Managers to the Issue, have finalized allocation of 17,81,200 Equity shares having face value of ₹10 each, to Anchor Investors at Anchor Investor allocation price ₹343 per equity share (including share premium of ₹333.00 per Equity share) in the following manner:

Sr. No.	Name of Anchor Investors	No. of Equity Shares Allocated	No of Equity Shares allocated as % of Anchor Investor Portion	Bid Price (₹ Per Equity Share)	Total Amount allocated (in ₹)
1	ABAKKUS SMALL CAP FUND	2,91,600	16.37 %	343	10,00,18,800
2	CARNELIAN AIF CATEGORY I TRUST-SCHEME 1	2,81,600	15.81 %	343	9,65,88,800
3	ABAKKUS FLEXI EDGE FUND-I	2,27,600	12.78 %	343	7,80,66,800
4	BHARAT VENTURE OPPORTUNITIES FUND	2,00,000	11.23 %	343	6,86,00,000
5	INDIA MAX INVESTMENT FUND LIMITED	1,43,200	8.04 %	343	4,91,17,600
6	SANSHI FUND-I	1,43,200	8.04 %	343	4,91,17,600
7	MERU INVESTMENT FUND PCC-CELL 1	87,600	4.92 %	343	3,00,46,800
8	TIGER STRATEGIES FUND -I	58,400	3.28 %	343	2,00,31,200
9	FINAVENUE CAPITAL TRUST - FINAVENUE GROWTH FUND	57,200	3.21 %	343	1,96,19,600

Q-LINE BIOTECH LIMITED

Samir Singh
Managing Director & Chairman

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

10	HEM GROWTH OPPORTUNITIES FUND	57,200	3.21 %	343	1,96,19,600
11	360 ONE LVF TREASURY SOLUTIONS FUND	29,200	1.64 %	343	1,00,15,600
12	HDFC BANK LIMITED	29,200	1.64 %	343	1,00,15,600
13	INNOVATIVE VISION FUND	29,200	1.64 %	343	1,00,15,600
14	NAVBHARAT INVESTMENT TRUST- NAVBHARAT INVESTMENT OPPORTUNITIES FUND	29,200	1.64 %	343	1,00,15,600
15	RAJASTHAN GLOBAL SECURITIES PRIVATE LIMITED	29,200	1.64 %	343	1,00,15,600
16	RELIGO COMMODITIES VENTURES TRUST- RELIGO COMMODITIES VENTURES FUND	29,200	1.64 %	343	1,00,15,600
17	SUNRISE INVESTMENT TRUST- SUNRISE INVESTMENT OPPORTUNITIES FUND	29,200	1.64 %	343	1,00,15,600
18	TATTVAM AIF TRUST - AANJAY AGELESS AIF FUND	29,200	1.64 %	343	1,00,15,600
	TOTAL	17,81,200	100 %		61,09,51,600

Out of the total allocation of 17,81,200 Equity Shares to the Anchor Investors, 2,91,600 Equity Shares (i.e. 16.37% of the total allocation to Anchor Investors) were allocated to One (1) domestic mutual fund, which applied through a total of 1 schemes and Nil Equity Shares were allocated to life insurance companies. Set forth below is a scheme wise detail of allocation to such mutual funds, and details of allocation to life insurance companies:

Sr. No.	Name of scheme	No. of Equity Shares Allocated	No of Equity Shares allocated as % of Anchor Investor Portion	Bid Price (₹ Per Equity Share)	Total Amount allocated (in ₹)
1.	ABAKKUS SMALL CAP FUND	2,91,600	16.37	343	10,00,18,800

Q-LINE BIOTECH LIMITED

Samir K. Ray
Managing Director & Chairman

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

As per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, in case the Issue Price discovered through book building process is higher than the Anchor investor Allocation Price, Anchor investors will be required to pay the difference by the Anchor investor Pay-in Date as specified in the revised CAN. Further, as per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, from time to time, we shall abide by Schedule XIII, Part A, Clause 10 and all relevant sub-clauses.


Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the Red Herring Prospectus dated May 16, 2026 filed with the Registrar of Companies, Uttar Pradesh I to be read along with price band advertisement dated May 18, 2026.

We request you to make the above information public by disclosing the same on your website.

Thanking You

For Q-Line Biotech Limited

Q-LINE BIOTECH LIMITED



Managing Director & Chairman

Authorised Signatory

Name: Saurabh Garg

Designation: Managing Director

DIN: 02891621

Q-LINE BIOTECH LIMITED

(Formerly known as "Q-Line Biotech Private Limited")

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023

Delhi Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407

E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528